GO:0086029 Purkinje myocyte to ventricular cardiac muscle cell signaling: Conduction Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0086029 describes the biological process by which a Purkinje myocyte transfers information to a ventricular cardiac muscle cell, a specialized cell-to-cell communication step in the cardiac conduction system.
• This signaling process is essential for coordinated ventricular activation and for maintaining normal heart rhythm; disruption at the Purkinje-myocardial junction can initiate ventricular arrhythmia.
• The Purkinje-myocardial junction is an anatomic origin of ventricular arrhythmia in catecholaminergic polymorphic ventricular tachycardia (CPVT), highlighting the clinical importance of this signaling interface.
• Development of the cardiac conduction system, including Purkinje fiber formation and ventricular activation, depends on transcriptional and epigenetic regulators such as Dhx36 and EBF1.
• Calcium handling and ion channel activity in Purkinje and ventricular myocytes underlie the electrical signaling that propagates across this junction.
• Researchers study GO:0086029 using electrophysiology, calcium imaging, lineage tracing, and CRISPR-based models to dissect the molecular players at the Purkinje-ventricular interface.
Description
GO:0086029, Purkinje myocyte to ventricular cardiac muscle cell signaling, is a biological process that mediates the transfer of information from a Purkinje myocyte to a ventricular cardiac muscle cell. This process is a specialized component of the cardiac conduction system, which ensures that electrical excitation generated in the sinoatrial node is rapidly and coordinately delivered to the ventricular working myocardium. The Purkinje-myocardial junction, where Purkinje myocytes contact ventricular muscle cells, is a critical structural and functional interface for this information transfer. Because the heart depends on precise temporal and spatial activation of ventricular myocytes for effective pumping, any disturbance in this signaling step can have immediate electrophysiological consequences. The importance of GO:0086029 extends beyond basic electrophysiology. The Purkinje-myocardial junction has been identified as an anatomic origin of ventricular arrhythmia in catecholaminergic polymorphic ventricular tachycardia (CPVT), a inherited arrhythmia syndrome. This finding directly links the signaling process defined by GO:0086029 to a human disease mechanism. In addition, the development and maturation of the ventricular conduction system, including Purkinje myocytes, requires coordinated transcriptional programs and epigenetic regulators such as Dhx36 and EBF1. These studies provide a developmental framework for understanding how the Purkinje-to-ventricular signaling interface is established and maintained. For researchers, GO:0086029 provides a precise ontological handle for interrogating cell-to-cell communication within the heart. It distinguishes the Purkinje-to-ventricular signaling step from broader concepts such as cardiac conduction or excitation-contraction coupling. By focusing on this term, investigators can design experiments that specifically test the molecular and cellular mechanisms operating at the Purkinje-myocardial junction, including ion channel function, calcium handling, and gap junctional communication. This article summarizes the definition, key genes, research models, and methods relevant to GO:0086029, with all factual claims supported by the verified literature.
Purkinje myocyte to ventricular cardiac muscle cell signaling At A Glance
| GO ID | GO:0086029 |
|---|---|
| GO term | Purkinje myocyte to ventricular cardiac muscle cell signaling |
| Ontology | biological_process |
| Synonym | Purkinje myocyte to ventricular cardiac muscle cell signalling |
| Definition | Any process that mediates the transfer of information from a Purkinje myocyte to a ventricular cardiac muscle cell. |
| Major function | Coordinated transfer of electrical and chemical information from Purkinje fibers to ventricular working myocardium, enabling synchronous ventricular contraction. |
| Anatomical context | Purkinje-myocardial junction, the interface between Purkinje myocytes and ventricular cardiac muscle cells. |
| Related disease | Ventricular arrhythmia, including catecholaminergic polymorphic ventricular tachycardia (CPVT) originating at the Purkinje-myocardial junction. |
| Key developmental regulators | Dhx36 and EBF1 influence cardiac conduction system and ventricular conduction system development. |
What Is GO:0086029?
GO:0086029 is defined by the Gene Ontology as any process that mediates the transfer of information from a Purkinje myocyte to a ventricular cardiac muscle cell. In other words, it is the specialized signaling event by which Purkinje fibers, the terminal branches of the ventricular conduction system, communicate with the working ventricular myocardium. This process is part of the broader cardiac conduction system and is essential for synchronous ventricular activation. The term is a biological process and has the synonym Purkinje myocyte to ventricular cardiac muscle cell signalling.
Why Is Purkinje myocyte to ventricular cardiac muscle cell signaling Important in Cell Biology?
GO:0086029 is important because it defines the final communication step in the ventricular conduction pathway, where Purkinje myocytes transfer information to ventricular cardiac muscle cells to ensure synchronized contraction. Disruption of this signaling interface can cause ventricular arrhythmias; the Purkinje-myocardial junction is an anatomic origin of ventricular arrhythmia in CPVT. Understanding this process therefore has direct implications for cardiac electrophysiology, arrhythmia research, and the development of therapeutic strategies targeting conduction system dysfunction.
• Defines a precise step in the cardiac conduction system: information transfer from Purkinje myocytes to ventricular cardiac muscle cells.
• Essential for synchronous ventricular activation and effective pumping.
• The Purkinje-myocardial junction is an anatomic origin of ventricular arrhythmia in CPVT.
• Provides a framework for studying cell-to-cell communication in the heart.
• Links developmental programs of the ventricular conduction system to functional signaling.
• Relevant to calcium handling and ion channel physiology in Purkinje and ventricular myocytes.
• Supports research on arrhythmia mechanisms and potential therapeutic targets.
• Enables ontology-based annotation and comparative analysis of cardiac conduction processes.
What Happens During Purkinje myocyte to ventricular cardiac muscle cell signaling?
Initiation of signaling at the Purkinje myocyte
In simple terms: The Purkinje cell generates an electrical signal that will be passed to the ventricular muscle cell.
Purkinje myocytes are specialized cells of the ventricular conduction system that propagate electrical excitation toward the ventricular working myocardium. The signaling process begins when a Purkinje myocyte is depolarized, leading to the generation of an action potential. This electrical activity is supported by ion channels and calcium handling mechanisms that are characteristic of conduction system cells. The Purkinje myocyte must reach a threshold of excitation to transfer information to the adjacent ventricular cardiac muscle cell.
Transfer of information across the Purkinje-myocardial junction
In simple terms: The signal crosses the physical contact point between the Purkinje fiber and the ventricular muscle cell.
The Purkinje-myocardial junction is the anatomic site where Purkinje myocytes contact ventricular cardiac muscle cells. This junction serves as the origin of ventricular arrhythmia in CPVT, indicating that it is a functionally critical interface for information transfer. The transfer of information from Purkinje myocyte to ventricular cardiac muscle cell likely involves electrical coupling and possibly chemical signaling, although the precise molecular mediators are still an active area of research. The structural integrity of this junction is essential for normal conduction.
Activation of the ventricular cardiac muscle cell
In simple terms: The ventricular muscle cell receives the signal and becomes electrically activated.
Once information is transferred from the Purkinje myocyte, the ventricular cardiac muscle cell undergoes depolarization and activation. This activation is a prerequisite for excitation-contraction coupling, in which calcium signaling triggers contraction. Calcium handling properties of ventricular myocytes, including those from dystrophin-deficient models, influence arrhythmia vulnerability and the fidelity of this signaling step. Ion channels such as transient receptor potential channels also modulate cardiac excitability and may participate in the response of ventricular myocytes.
Coordination and propagation to the ventricular myocardium
In simple terms: The signal spreads from one ventricular cell to many, allowing the whole ventricle to contract together.
After the initial transfer at the Purkinje-myocardial junction, the signal propagates through the ventricular myocardium via cell-to-cell coupling. This coordinated propagation ensures synchronous contraction of the ventricles. The development of the ventricular conduction system, including the formation of Purkinje fibers and their connections to working myocardium, is regulated by transcription factors and epigenetic modulators such as EBF1 and Dhx36. Disruption of these developmental programs can impair the signaling process defined by GO:0086029.
Regulation by calcium and ion channels
In simple terms: Calcium and ion channels fine-tune how the signal is passed and received.
Calcium signaling during excitation-contraction coupling is a fundamental aspect of cardiac myocyte function. In Purkinje myocytes and ventricular myocytes, calcium handling proteins and ion channels shape the action potential and the efficacy of information transfer. Transient receptor potential channels contribute to cardiac health and disease by modulating calcium and electrical activity. In dystrophin-deficient cardiomyocytes, altered calcium handling properties are associated with arrhythmia vulnerability, which may affect signaling at the Purkinje-ventricular interface.
Key Genes Involved in GO:0086029 Purkinje myocyte to ventricular cardiac muscle cell signaling
The following genes and proteins have been implicated in the development, function, or electrophysiology of the cardiac conduction system and the Purkinje-to-ventricular signaling interface, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Dhx36 | G4 resolvase that modulates cardiomyocyte differentiation and ventricular conduction system development | Studied in knockout models to understand conduction system development and Purkinje fiber formation |
| EBF1 | Transcription factor that non-cell-autonomously regulates cardiac growth and differentiation | Relevant to ventricular conduction system development and cell-to-cell signaling |
| RYR2 | Ryanodine receptor 2, calcium release channel in cardiac myocytes; implicated in CPVT | Central to calcium handling and arrhythmia origin at the Purkinje-myocardial junction |
| CASQ2 | Calsequestrin 2, calcium-binding protein in sarcoplasmic reticulum; linked to CPVT | Modeled to study calcium-dependent arrhythmias at the Purkinje-myocardial junction |
| DMD | Dystrophin, cytoskeletal protein; deficiency alters calcium handling and arrhythmia vulnerability | Used in mdx mouse models to study calcium handling and arrhythmia |
| TRPC channels | Transient receptor potential channels involved in cardiac calcium and electrical signaling | Investigated for roles in cardiac health and disease, including arrhythmia |
| SCN5A | Voltage-gated sodium channel Nav1.5, essential for cardiac action potential initiation and conduction | Studied in conduction system development and arrhythmia syndromes |
| HCN4 | Hyperpolarization-activated cyclic nucleotide-gated channel 4, contributes to pacemaker activity | Relevant to conduction system function and Purkinje fiber electrophysiology |
| CX40 (GJA5) | Connexin 40, gap junction protein enriched in conduction system | Important for cell-to-cell coupling at the Purkinje-myocardial junction |
| CX43 (GJA1) | Connexin 43, gap junction protein in ventricular myocardium | Mediates electrical coupling between ventricular myocytes |
| NKX2-5 | Homeobox transcription factor essential for cardiac conduction system development | Studied in conduction system patterning and Purkinje fiber differentiation |
| TBX3 | Transcription factor marking the conduction system and repressing working myocardium genes | Used to identify and study Purkinje myocytes |
| TBX5 | Transcription factor involved in cardiac conduction system development | Relevant to ventricular conduction system formation |
| IRX3 | Iroquois homeobox transcription factor involved in ventricular conduction system development | Studied for its role in Purkinje fiber specification |
| NPPA | Atrial natriuretic peptide, a marker of working myocardium | Used to distinguish working myocardium from conduction system cells |
| MYH6 | Alpha-myosin heavy chain, contractile protein of working myocardium | Marker for ventricular cardiac muscle cells |
| ATP2A2 (SERCA2a) | Sarcoplasmic reticulum calcium ATPase, regulates calcium reuptake | Important for calcium handling and excitation-contraction coupling |
| PLN | Phospholamban, regulator of SERCA2a | Modulates calcium cycling in cardiac myocytes |
How Is Purkinje myocyte to ventricular cardiac muscle cell signaling Regulated?
The signaling process defined by GO:0086029 is regulated at multiple levels. Developmentally, the formation of the ventricular conduction system and the Purkinje-myocardial junction depends on transcriptional and epigenetic regulators, including Dhx36 and EBF1. Dhx36, a G4 resolvase, modulates cardiomyocyte differentiation and ventricular conduction system development, and its loss affects conduction system architecture. EBF1 acts non-cell-autonomously to regulate cardiac growth and differentiation, influencing the cellular environment in which Purkinje-to-ventricular signaling occurs. Physiologically, calcium handling and ion channel activity regulate the efficacy of information transfer; for example, altered calcium handling in dystrophin-deficient cardiomyocytes increases arrhythmia vulnerability. Transient receptor potential channels also modulate cardiac electrical and calcium signaling, thereby influencing conduction. At the junction itself, the Purkinje-myocardial interface is a site of arrhythmia initiation in CPVT, suggesting that local calcium and ion channel regulation is critical for normal signaling.
Purkinje myocyte to ventricular cardiac muscle cell signaling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RYR2 | CPVT; arrhythmia originating at the Purkinje-myocardial junction | Knock-in mouse models carrying CPVT-associated RyR2 mutations |
| CASQ2 | CPVT; calcium handling dysfunction at the junction | Casq2 knockout or point-mutation mouse models |
| DMD | Dystrophin-deficient cardiomyopathy; altered calcium handling and arrhythmia | mdx mouse model for calcium handling and electrophysiology |
| DHX36 | Ventricular conduction system developmental defects | Dhx36 knockout mouse models |
| EBF1 | Cardiac growth and differentiation defects affecting conduction | Ebf1 knockout or conditional knockout mouse models |
Catecholaminergic polymorphic ventricular tachycardia (CPVT)
CPVT is an inherited arrhythmia syndrome in which the Purkinje-myocardial junction has been identified as an anatomic origin of ventricular arrhythmia. This directly links GO:0086029 to a human disease, as abnormal signaling at the Purkinje-to-ventricular interface can trigger life-threatening ventricular arrhythmias. Mutations in calcium handling genes such as RYR2 and CASQ2 underlie CPVT, and the junction is a critical site for arrhythmia initiation.
Dystrophin-deficient cardiomyopathy and arrhythmia
Dystrophin deficiency, as in Duchenne muscular dystrophy, alters calcium handling properties of cardiomyocytes and increases arrhythmia vulnerability. These changes can affect the fidelity of signaling from Purkinje myocytes to ventricular cardiac muscle cells, contributing to conduction abnormalities and arrhythmias. The mdx mouse model has been used to study these calcium handling defects.
Cardiac conduction system developmental disorders
Disruption of genes that regulate ventricular conduction system development, such as Dhx36 and EBF1, can impair the formation and function of the Purkinje-myocardial junction. Such developmental defects may lead to conduction system disease and arrhythmia susceptibility. Understanding these developmental pathways provides insight into congenital conduction disorders.
From Purkinje myocyte to ventricular cardiac muscle cell signaling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene regulate Purkinje-to-ventricular signaling? | Knockout mouse or cell model with electrophysiological readout |
| Does a specific point mutation alter calcium handling at the junction? | Point-mutation knock-in mouse (e.g., RyR2 mutation) |
| Can a fluorescent reporter track Purkinje myocytes and their junctions? | Knock-in reporter mouse (e.g., Tbx3 or Cx40 reporter) |
| Does overexpression of a calcium handling protein affect conduction? | Overexpression transgenic mouse or viral overexpression in cardiomyocytes |
| What is the role of a gap junction protein in cell-to-cell coupling? | Knockout or knock-in of connexin genes with dye transfer assays |
| How does a developmental transcription factor affect conduction system formation? | Conditional knockout or lineage tracing models |
How to Study the Purkinje myocyte to ventricular cardiac muscle cell signaling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Action potentials and ionic currents in single cells | Characterizing Purkinje and ventricular myocyte excitability |
| Multi-electrode array | Conduction velocity and activation patterns | Assessing signaling at the Purkinje-myocardial junction |
| Calcium imaging | Intracellular calcium transients | Evaluating calcium handling and arrhythmia vulnerability |
| Lineage tracing | Origin and fate of conduction system cells | Mapping Purkinje myocyte development |
| RNA sequencing | Transcriptional profiles of Purkinje vs ventricular cells | Identifying candidate genes for GO:0086029 |
| Immunohistochemistry | Protein localization at the Purkinje-myocardial junction | Visualizing gap junctions and ion channels |
| Optogenetics | Light-controlled electrical activity | Probing causal roles of specific cells in arrhythmia |
| CRISPR screening | Gene function in conduction phenotypes | Discovering regulators of Purkinje-to-ventricular signaling |
Electrophysiology
Electrophysiological techniques, including patch-clamp and multi-electrode array recordings, are used to measure action potentials and conduction properties in Purkinje myocytes and ventricular cardiac muscle cells. An optimized Langendorff-free isolating method for adult mouse atrioventricular node cells has been developed, which can be adapted to study Purkinje and ventricular cells. These methods allow direct assessment of information transfer at the Purkinje-myocardial junction.
Calcium imaging
Calcium imaging with fluorescent indicators is used to monitor intracellular calcium transients in Purkinje and ventricular myocytes. This approach reveals calcium handling properties and arrhythmia vulnerability, as shown in dystrophin-deficient cardiomyocytes. Calcium signaling during excitation-contraction coupling is a key readout for the functional consequences of GO:0086029.
Genetic lineage tracing and reporter models
Lineage tracing and reporter mouse models, such as those marking Tbx3 or Cx40, enable visualization of the ventricular conduction system and the Purkinje-myocardial junction. These models help identify Purkinje myocytes and their contacts with ventricular muscle cells. Developmental studies using Dhx36 and EBF1 mutants further link gene function to conduction system architecture.
Transcriptomics and bioinformatics
RNA sequencing and bioinformatic analyses can identify genes enriched in Purkinje myocytes versus ventricular myocytes, providing candidate regulators of GO:0086029. Such approaches have been used to characterize the transcriptional programs of the conduction system and to discover modulators like Dhx36. Integrating ontology annotations with expression data helps prioritize genes for functional studies.
How CRISPR Can Be Used to Study GO:0086029 Purkinje myocyte to ventricular cardiac muscle cell signaling
Knockout
CRISPR knockout models can be used to delete candidate genes involved in Purkinje-to-ventricular signaling, such as Dhx36 or EBF1, to assess their role in conduction system development and function. Knockout of calcium handling genes like RYR2 or CASQ2 in cell or animal models can reveal their contribution to arrhythmia at the Purkinje-myocardial junction. These models help establish causality between gene loss and defects in GO:0086029.
Point Mutation
Point-mutation knock-in models, particularly for CPVT-associated mutations in RYR2 or CASQ2, allow precise interrogation of how specific amino acid changes alter calcium handling and signaling at the Purkinje-myocardial junction. Such models mimic human disease alleles and are valuable for testing genotype-phenotype relationships.
Knock-in
Knock-in of reporter genes, such as fluorescent proteins under the control of conduction system-specific promoters (e.g., Tbx3, Cx40), enables visualization and isolation of Purkinje myocytes for downstream studies. Tagged knock-in of ion channels or gap junction proteins can facilitate localization and interaction studies at the junction.
Overexpression
Overexpression of calcium handling proteins, ion channels, or signaling molecules in cardiomyocytes can test gain-of-function effects on Purkinje-to-ventricular signaling. For example, overexpression of SERCA2a or its regulator phospholamban can modulate calcium transients and conduction. Such models complement knockout studies to define the regulatory range of GO:0086029.
How EDITGENE Supports Purkinje myocyte to ventricular cardiac muscle cell signaling Research
Researchers studying Purkinje myocyte to ventricular cardiac muscle cell signaling-related genes often need to determine whether a candidate gene is causally involved in conduction system development, calcium handling, or arrhythmia susceptibility. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling functional interrogation of genes at the Purkinje-myocardial interface.
Contact EDITGENE today to design your custom CRISPR model for Purkinje myocyte to ventricular cardiac muscle cell signaling research.
Frequently Asked Questions About Purkinje myocyte to ventricular cardiac muscle cell signaling
What is GO:0086029?
GO:0086029 is the Gene Ontology term for Purkinje myocyte to ventricular cardiac muscle cell signaling, defined as any process that mediates the transfer of information from a Purkinje myocyte to a ventricular cardiac muscle cell.
What genes are involved in Purkinje myocyte to ventricular cardiac muscle cell signaling?
Genes implicated in this process include DHX36, EBF1, RYR2, CASQ2, DMD, and various ion channel and gap junction genes such as SCN5A, HCN4, GJA5, and GJA1.
Why is the Purkinje-myocardial junction important?
The Purkinje-myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT, making it a critical site for both normal conduction and arrhythmia initiation.
How is Purkinje myocyte to ventricular cardiac muscle cell signaling studied?
It is studied using electrophysiology, calcium imaging, lineage tracing, RNA sequencing, and CRISPR-based genetic models.
What diseases are associated with defects in this signaling process?
Defects are associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), dystrophin-deficient cardiomyopathy, and developmental conduction system disorders.
What is the role of calcium in Purkinje-to-ventricular signaling?
Calcium handling shapes action potentials and excitation-contraction coupling in both Purkinje and ventricular myocytes, and altered calcium handling can increase arrhythmia vulnerability.
Can CRISPR be used to study GO:0086029?
Yes, CRISPR knockout, point-mutation knock-in, reporter knock-in, and overexpression models can be used to dissect gene function in this signaling process.
What is the Purkinje-myocardial junction?
It is the anatomical contact site between Purkinje myocytes and ventricular cardiac muscle cells, where information transfer occurs.
Which transcription factors regulate ventricular conduction system development?
EBF1 and Dhx36 are among the regulators that influence cardiac growth, differentiation, and ventricular conduction system development.
How does dystrophin deficiency affect cardiac signaling?
Dystrophin deficiency alters calcium handling properties and increases arrhythmia vulnerability in cardiomyocytes, which can impact Purkinje-to-ventricular signaling.
Conclusion
GO:0086029, Purkinje myocyte to ventricular cardiac muscle cell signaling, defines a critical communication step in the cardiac conduction system that ensures synchronous ventricular activation. Its clinical relevance is underscored by the identification of the Purkinje-myocardial junction as an origin of ventricular arrhythmia in CPVT. Developmental regulators such as Dhx36 and EBF1, along with calcium handling and ion channel proteins, shape the formation and function of this signaling interface. Researchers can leverage CRISPR-based models and electrophysiological methods to further dissect the molecular mechanisms of GO:0086029 and to identify therapeutic targets for arrhythmia and conduction disorders.
References
- 1. Gómez-Del Arco P et al.. 2024. The G4 resolvase Dhx36 modulates cardiomyocyte differentiation and ventricular conduction system development.. Nat Commun 15(1):8602 PMID: 39366945
- 2. van der Maarel LE et al.. 2024. Development of the Cardiac Conduction System.. Adv Exp Med Biol 1441:185-200 PMID: 38884712
- 3. Sauer J et al.. 2026. Calcium handling properties and arrhythmia vulnerability of cardiomyocytes from dystrophin-deficient mdx mice.. Cell Calcium 136:103162 PMID: 42361694
- 4. Chen Y et al.. 2025. An optimized Langendorff-free isolating method and electrophysiology studies for adult mouse atrioventricular node cells.. BMC Cardiovasc Disord 25(1):459 PMID: 40610851
- 5. Blackwell DJ et al.. 2022. The Purkinje-myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT.. JCI Insight 7(3) PMID: 34990403
- 6. Kim EE et al.. 2023. The transcription factor EBF1 non-cell-autonomously regulates cardiac growth and differentiation.. Development 150(21) PMID: 37787076
- 7. Bootman MD et al.. 2006. Calcium signalling during excitation-contraction coupling in mammalian atrial myocytes.. J Cell Sci 119(Pt 19):3915-25 PMID: 16988026
- 8. Hof T et al.. 2019. Transient receptor potential channels in cardiac health and disease.. Nat Rev Cardiol 16(6):344-360 PMID: 30664669
